Quarterly ResultAug 5, 2026, 04:13 PM
KORU Medical Systems Q2 Revenue $12.0M, Net Income $0.25M; Updates 2026 Guidance
AI Summary
KORU Medical Systems reported strong second-quarter 2026 financial results, with net revenues growing 18.2% to $12.0 million and net income improving 222% to $0.25 million. The company also updated its full-year 2026 guidance, narrowing revenue expectations to $47.5 - $48.5 million and raising gross margin to 62% - 64%. Strategic highlights include the acquisition of a connected monitoring technology asset and a shift in its U.S. oncology market entry strategy, including withdrawing a 510(k) application.
Key Highlights
- Q2 2026 net revenues increased 18.2% to $12.0 million.
- Q2 2026 net income improved 222% to $0.25 million ($0.01 per diluted share).
- Q2 2026 gross profit grew 20% to $7.8 million, with gross margin at 65.1%.
- Acquired a connected monitoring technology asset for potential platform enhancement.
- Withdrew U.S. 510(k) application for FreedomEDGE® with Phesgo®; shifting oncology focus.
- Updated full-year 2026 revenue guidance to $47.5 - $48.5 million.
- Updated full-year 2026 gross margin guidance to 62% - 64%.
- Reiterated positive adjusted EBITDA for full year 2026.
Price Impact
More from KRMD